首页> 美国卫生研究院文献>AAPS PharmSciTech >Nanocrystallization by Evaporative Antisolvent Technique for Solubility and Bioavailability Enhancement of Telmisartan
【2h】

Nanocrystallization by Evaporative Antisolvent Technique for Solubility and Bioavailability Enhancement of Telmisartan

机译:蒸发反溶剂技术进行纳米结晶可提高替米沙坦的溶解度和生物利用度

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Telmisartan is an orally active nonpeptide angiotensin II receptor antagonist used in the management of hypertension. It is a Biopharmaceutics Classification System class II drug having aqueous solubility of 9.9 μg/ml. Telmisartan (TEL) nanocrystals were prepared by evaporative antisolvent precipitation technique using different stabilizers as PVPK30, TPGS, Poloxamer 188, and PEG 6000 in combination or singly. The nanosuspensions were characterized in terms of particle size distribution, zeta potential, and polydispersity index. The suspension containing PVPK30 and TPGS (1:1) showed least average particle size of 82.63 nm and polydispersity index of 0.472. The zeta potential of nanosuspensions ranged between 6.54 and 10.8 mV. An increase of 116.45% was evident in the specific surface area of the freeze-dried product. Contact angle of nanoparticles was also lowered to 27° as compared to 50.8° for TEL. Saturation solubility studies in various media revealed a significant increase in comparison to plain drug. An increase of 3.74× in saturation solubility in FaSSIF and 5.02× in FeSSIF was seen. In vitro dissolution profile of nanosuspension coated on pellets revealed release of 85% in water, 95% in 0.1 N HCl, and 75% in phosphate buffer in 30 min. Nanosuspensions were found to be stable in the presence of univalent and bivalent electrolytes. A tenfold increase in bioavailability was evident. Nanoparticles of telmisartan prepared by bottom-up technique proved to be effective in improving the oral bioavailability as a result of enhanced solubility and dissolution rate.
机译:替米沙坦是一种用于治疗高血压的口服活性非肽血管紧张素II受体拮抗剂。这是一种生物制药分类系统II类药物,其水溶性为9.9μg/ ml。使用不同的稳定剂,如PVPK30,TPGS,泊洛沙姆188和PEG 6000,通过蒸发反溶剂沉淀技术制备或联合使用替米沙坦(TEL)纳米晶体。纳米悬浮液的特征在于粒度分布,ζ电势和多分散指数。含有PVPK30和TPGS(1:1)的悬浮液的最小平均粒径为82.63 nm,多分散指数为0.472。纳米悬浮液的Zeta电位在6.54和10.8 mV之间。冻干产品的比表面积明显增加了116.45%。与TEL的50.8°相比,纳米颗粒的接触角也降低到27°。在各种介质中的饱和溶解度研究表明,与普通药物相比,显着增加。 FaSSIF的饱和溶解度增加了3.74倍,FeSSIF的饱和溶解度增加了5.02倍。纳米颗粒悬浮液的体外溶出曲线显示,在30分钟内,其在水中的释放率为85%,在0.1N HCl中释放为95%,在磷酸盐缓冲液中释放为75%。发现纳米悬浮液在单价和二价电解质的存在下是稳定的。生物利用度提高了十倍。自下而上技术制备的替米沙坦纳米颗粒由于增加了溶解度和溶出度,被证明可有效改善口服生物利用度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号